Doxcycline-inducible and brain-specific HIV-1 Tat transgenic mice

Research Tool

Human immunodeficiency virus type 1 (HIV-1) Tat protein has been implicated in the pathogenesis of a number of AIDS-related disorders including HIV-induced neuropathogenesis. However, most of the studies demonstrating Tat neurotoxicity have been performed in vitro. The mechanisms of Tat neurotoxicity should be addressed in the context of a whole organism and in a manner that allows for characterization of pathologies specific to Tat expression in the brain. Indiana University researchers have developed a doxycycline-inducible brain-specific (GFAP promoter) Tat transgenic mouse model.

Ref: Am J Pathol. 2003 May;162(5):1693-707.

Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline.

Kim BO, Liu Y, Ruan Y, Xu ZC, Schantz L, He JJ.

These transgenic mice offer an in vivo model for delineating the molecular mechanisms of Tat neurotoxicity These transgenic mice offer a tool for developing and evaluating therapeutic strategies for treating HIV-associated neurological disorders

Inventor(s): Johnny J. He, Ph.D.

Type of Offer: Licensing

Next Patent »
« More Tools Patents
« More Medical Patents

Share on      

CrowdSell Your Patent